Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Marco Galluzzo, Giacomo Caldarola, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1299-1310
Open Access | Times Cited: 24

Showing 24 citing articles:

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
Matteo Megna, Luca Potestio, Elisa Camela, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 43
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 10
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
Valerio Caputo, Claudia Strafella, Terenzio Cosio, et al.
Genes (2021) Vol. 12, Iss. 9, pp. 1398-1398
Open Access | Times Cited: 40
The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition
Francesco Messina, Stefano Piaserico
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2443-2454
Closed Access | Times Cited: 23
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Dimitrios Rigopoulos, Eleftheria Tampouratzi, Charalampos Angelakopoulos, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 6, pp. 1121-1130
Closed Access | Times Cited: 4
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Brodalumab in plaque psoriasis: Real‐world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks
Natalia Rompoti, Maria Politou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 689-697
Closed Access | Times Cited: 18
Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece)
Dimitrios Rigopoulos, John Katsantonis, O. Neofotistou, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024152-e2024152
Open Access | Times Cited: 3
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
M. E. van Muijen, Sarah E. Thomas, Hans Groenewoud, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00712-adv00712
Open Access | Times Cited: 13
Interleukin 17 and Its Involvement in Renal Cell Carcinoma
Michał Jarocki, Julia Karska, Szymon Kowalski, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4973-4973
Open Access | Times Cited: 13
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 8
Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis up to 3 years
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 7, pp. 922-928
Closed Access | Times Cited: 2
Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
Cathrine Dawn Büttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Drugs in R&D (2023) Vol. 23, Iss. 2, pp. 155-163
Open Access | Times Cited: 6
Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals
Eleftheria Tampouratzi, Markos Papakonstantis, John Katsantonis, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 7
Open Access | Times Cited: 9
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks
Luca Mastorino, Caterina Cariti, Sara Susca, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 8, pp. 3211-3213
Closed Access | Times Cited: 8
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
Philip Hampton, Emma Borg, Jes B. Hansen, et al.
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 123-131
Open Access | Times Cited: 8
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Antonio Sahuquillo‐Torralba, Mercedes Hospital‐Gil, E. Vilarrasa‐Rull, et al.
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 4
Closed Access | Times Cited: 3
Interleukin 17 and Its Involvement in Renal Cell Carcinoma
Michał Jarocki, Julia Karska, Szymon Kowalski, et al.
(2022)
Open Access | Times Cited: 5
Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece
Evangelia Papadavid, Efterpi Zafeiriou, Sophia Georgiou, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 7, pp. 3053-3059
Closed Access | Times Cited: 5
Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology
Caterina Lanna, Sara Lambiase, Ruslana Gaeta Shumak, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 10, pp. 1209-1224
Closed Access | Times Cited: 2
The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis
Jenny M. Norlin, Sofia Löfvendahl, Marcus Schmitt‐Egenolf
Dermatology (2022) Vol. 239, Iss. 2, pp. 262-266
Open Access | Times Cited: 1
Antipsoriatics

Reactions Weekly (2022) Vol. 1896, Iss. 1, pp. 56-56
Closed Access
Page 1

Scroll to top